FIG. 5.
(A) COL1A and (B) α-SMA RNA content of HCFs cultured on cardiac ECM, lung ECM, and individual ECM components with a 48-h incubation with β3 integrin blocking antibodies normalized to RNA content of NHLFs and HCFs without integrin blocking antibodies. (C) COL1A and (D) α-SMA RNA content of HCFs cultured on cardiac ECM, lung ECM, and individual ECM components with a 48-h incubation with β4 integrin blocking antibodies normalized to RNA content of NHLFs and HCFs without integrin blocking antibodies (+B3, with blocking antibody to integrin β3; −B3, without blocking antibody to integrin β3; +B4, with blocking antibody to integrin β4; −B4, without blocking antibody to integrin β4; coll, type 1 collagen; FN, fibronectin; LECM1, lung ECM; CECM2, cardiac ECM derived from second condition—see text for details). *The set of conditions is statistically different from each other as shown by ANOVA (p<0.05). Error bars represent mean±SD. Color images available online at www.liebertpub.com/tea